Endocrinology, Vol 136, 2435-2441, Copyright © 1995 by Endocrine Society

ARTICLES

Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats

HZ Ke, HA Simmons, CM Pirie, DT Crawford and DD Thompson
Department of Cardiovascular and Metabolic Diseases, Pfizer, Inc., Groton, Connecticut 06340, USA.

The purpose of this study was to determine the effects of droloxifene (DRO), a new estrogen antagonist/agonist, on bone turnover, bone mass, total serum cholesterol, and uterine weight in rats made estrogen deficient by ovariectomy. Sprague-Dawley female rats were ovariectomized (OVX) or sham operated (sham) at 5 months of age and treated with 17 beta-estradiol (E2) at 30 micrograms/kg, sc, daily or with DRO at 5, 10, or 20 mg/kg.day, orally, for 4 weeks. At the time of death, body weight gain, uterine weight, and total serum cholesterol were measured. Bone area, bone mineral content (BMC), and bone mineral density (BMD) of whole femora, distal femoral metaphyses, femoral shaft, and proximal femora were determined ex vivo using dual energy x- ray absorptiometry. Static and dynamic cancellous bone histomorphometric analysis of proximal tibial metaphyses was performed in double fluorescent labeled, undecalcified, 4- and 10-microns longitudinal sections. Body weight gain in E2-treated OVX rats was significantly reduced compared to that in OVX controls, but was not different from that in sham controls. Body weight gain in DRO-treated OVX rats was decreased significantly compared to that in both sham and OVX controls. In OVX rats, uterine weight was completely preserved by treatment with E2. Uterine weight in DRO-treated OVX rats was slightly, but significantly, increased from the vehicle-treated control value, and was significantly lower than that in sham controls and E2-treated OVX rats. Treatment with sc injection of E2 in OVX rats had no effect on total serum cholesterol, whereas OVX rats orally treated with DRO at 5-20 mg/kg.day decreased total serum cholesterol by 33-46% compared to levels in sham and OVX controls. Compared to sham controls, OVX decreased BMC and BMD of distal femoral metaphyses, increased BMD of the femoral shaft, and had no effect on BMC and BMD of whole femora and proximal femora. Treatment with either E2 or DRO prevented these changes induced by OVX. Proximal tibial metaphyseal trabecular bone volume and trabecular number were increased, and trabecular separation, percent osteoclast perimeter, osteoclast number, percent mineralizing perimeter, mineral apposition rate, bone formation rate, and bone turnover rate were decreased in 5, 10, or 20 mg/kg.day DRO-treated OVX rats compared to OVX controls. These cancellous bone histomorphometric indexes in DRO treated OVX rats did not differ from those in E2-treated OVX rats or sham controls, suggesting that DRO completely prevented the increases in bone turnover and the decrease in bone mass induced by OVX in rats.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				M. J. Perry, S. Gujra, T. Whitworth, and J. H. Tobias Tamoxifen Stimulates Cancellous Bone Formation in Long Bones of Female Mice Endocrinology, March 1, 2005; 146(3): 1060 - 1065. [Abstract] [Full Text] [PDF]

				B. Antus, S. Liu, Y. Yao, H. Zou, E. Song, J. Lutz, and U. Heemann Effects of progesterone and selective oestrogen receptor modulators on chronic allograft nephropathy in rats Nephrol. Dial. Transplant., February 1, 2005; 20(2): 329 - 335. [Abstract] [Full Text] [PDF]

				M. E. Nuttall, G. B. Stroup, P. W. Fisher, D. P. Nadeau, M. Gowen, and L. J. Suva Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells Am J Physiol Cell Physiol, November 1, 2000; 279(5): C1550 - C1557. [Abstract] [Full Text] [PDF]

				C. K. Osborne and S. A. W. Fuqua Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use J. Clin. Oncol., September 17, 2000; 18(17): 3172 - 3186. [Abstract] [Full Text] [PDF]

				H. Z. Ke, H. Qi, D. T. Crawford, K. L. Chidsey-Frink, H. A. Simmons, and D. D. Thompson Lasofoxifene (CP-336,156), a Selective Estrogen Receptor Modulator, Prevents Bone Loss Induced by Aging and Orchidectomy in the Adult Rat Endocrinology, April 1, 2000; 141(4): 1338 - 1344. [Abstract] [Full Text] [PDF]

				Q. Qu, H. Zheng, J. Dahllund, A. Laine, N. Cockcroft, Z. Peng, M. Koskinen, K. Hemminki, L. Kangas, K. Vaananen, et al. Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats Endocrinology, February 1, 2000; 141(2): 809 - 820. [Abstract] [Full Text] [PDF]

				F. Squadrito, D. Altavilla, G. Squadrito, A. Saitta, D. Cucinotta, L. Minutoli, B. Deodato, M. Ferlito, G. M. Campo, A. Bova, et al. Genistein supplementation and estrogen replacement therapy improve endothelial dysfunction induced by ovariectomy in rats Cardiovasc Res, January 14, 2000; 45(2): 454 - 462. [Abstract] [Full Text] [PDF]

				F. Cosman and R. Lindsay Selective Estrogen Receptor Modulators: Clinical Spectrum Endocr. Rev., June 1, 1999; 20(3): 418 - 434. [Abstract] [Full Text]

				R. K. Dubey, Y. Y. Tyurina, V. A. Tyurin, D. G. Gillespie, R. A. Branch, E. K. Jackson, and V. E. Kagan Estrogen and Tamoxifen Metabolites Protect Smooth Muscle Cell Membrane Phospholipids Against Peroxidation and Inhibit Cell Growth Circ. Res., February 5, 1999; 84(2): 229 - 239. [Abstract] [Full Text] [PDF]

				M. E. Nuttall, J. N. Bradbeer, G. B. Stroup, D. P. Nadeau, S. J. Hoffman, H. Zhao, S. Rehm, and M. Gowen Idoxifene: A Novel Selective Estrogen Receptor Modulator Prevents Bone Loss and Lowers Cholesterol Levels in Ovariectomized Rats and Decreases Uterine Weight in Intact Rats Endocrinology, December 1, 1998; 139(12): 5224 - 5234. [Abstract] [Full Text] [PDF]

				J. D. Sibonga, H. Dobnig, R. M. Harden, and R. T. Turner Effect of the High-Affinity Estrogen Receptor Ligand ICI 182,780 on the Rat Tibia Endocrinology, September 1, 1998; 139(9): 3736 - 3742. [Abstract] [Full Text] [PDF]

				H. A. Simmons, C. M. Pirie, D. D. Thompson, and H. Z. Ke Parathyroid Hormone (1-34) Increased Total Body Bone Mass in Aged Female Rats J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 341 - 344. [Abstract] [Full Text]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]

				H. Z. Ke, V. M. Paralkar, W. A. Grasser, D. T. Crawford, H. Qi, H. A. Simmons, C. M. Pirie, K. L. Chidsey-Frink, T. A. Owen, S. L. Smock, et al. Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models Endocrinology, April 1, 1998; 139(4): 2068 - 2076. [Abstract] [Full Text] [PDF]

				M. S. Anthony, T. B. Clarkson, B. C. Bullock, and J. D. Wagner Soy Protein Versus Soy Phytoestrogens in the Prevention of Diet-Induced Coronary Artery Atherosclerosis of Male Cynomolgus Monkeys Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2524 - 2531. [Abstract] [Full Text]

				S. Luo, A. Sourla, C. Labrie, A. Belanger, and F. Labrie Combined Effects of Dehydroepiandrosterone and EM-800 on Bone Mass, Serum Lipids, and the Development of Dimethylbenz(A)Anthracene-Induced Mammary Carcinoma in the Rat Endocrinology, October 1, 1997; 138(10): 4435 - 4444. [Abstract] [Full Text] [PDF]

				P. Holm, M. Shalmi, N. Korsgaard, B. Guldhammer, S. O. Skouby, and S. Stender A Partial Estrogen Receptor Agonist With Strong Antiatherogenic Properties Without Noticeable Effect on Reproductive Tissue in Cholesterol-Fed Female and Male Rabbits Arterioscler. Thromb. Vasc. Biol., October 1, 1997; 17(10): 2264 - 2272. [Abstract] [Full Text]

				M. A. Jimenez, D. E. Magee, H. U. Bryant, and R. T. Turner Clomiphene Prevents Cancellous Bone Loss from Tibia of Ovariectomized Rats Endocrinology, May 1, 1997; 138(5): 1794 - 1800. [Abstract] [Full Text] [PDF]